Posted by AGORACOM-JC
at 4:37 PM on Tuesday, November 30th, 2021
HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing high value-added silicon products that are sought after by battery and electric vehicle manufacturers – but nobody has yet delivered – until now.
If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following:
To understand the importance and the implications of this milestone, this excerpt from the press release says it all:
The US patent covers the PUREVAP™ QRR innovative process, which permits the one-step transformation of quartz (SiO 2 ) into high purity silicon metal (from 99.5% to 99.99% Si) at reduced costs, energy input, and carbon footprint. This game-changing advantage means that the PUREVAP™ QRR process not only produces a higher purity silicon material than traditional processes, but it does not require the extremely pure feedstock needed by conventional processes. In fact, the process only requires 4.5 MT of raw material to make 1 MT of Silicon, versus the 6 MT required by conventional processes, a 25% reduction which potentially allows a 20% cash cost advantage versus the lowest cost traditional Silicon producer . Furthermore, as part of our ongoing strategy of protecting and strengthening the PUREVAP™ Intellectual Property Portfolio, a second patent application, focusing on a new and novel process was filed in 2019 and is presently advancing through the process.
Bernard Tourillon, President and CEO of HPQ commented,
“HPQ has been at the forefront of Low-Cost Green Silicon innovation developments since 2015, and getting this U.S. patent approval, combined with the ongoing commissioning of the GEN3 PUREVAP™ QRR pilot plant , has occurred at an opportune time, as demand continues to rise and bottlenecks we had foreseen are now occurring in the silicon supply chain. With ESG principles playing an active role in materials sourcing, the world is more aware of the difficulty of securing the ESG compliant Silicon needed to meet its renewable energy goals. The reality of chronic underinvestment in new technologies combined with the offshoring of Silicon production capacity, has created a massive opportunity for HPQ and its PUREVAP™ QRR patented process, as we are the only company to bring to market a new process to make Silicon that is perfectly suited to the new demands and realities of the Silicon market
Watch this great interview with $HPQ CEO Bernard Tourillon.
Steven McAuley, Chairman and CEO of Empower commented:
“This quarter marked the start of a new chapter for the Company and the Empower team. We launched The Medi-Collective brand and clinics, expanded Kai Labs’ facilities and completed the acquisition of MediSure. Each of these milestones is an intrinsic aspect of our strategic growth vision.“
Key Q3-2021 Highlights:
Revenue from continuing operations of $405,707 compared to $85,960 in Q3 2020, representing 372% year-over-year growth.
Revenue from continuing operations of $3,226,335 for nine months YTD 2021 compared to $222,690 for nine months YTD 2020, representing 1,349% year over year growth.
What does CEO Steven McAuley think of these results?
“With positive year-over-year growth coming out of this quarter, we will maximize our fully operational divisions’ capabilities and reach across Canada and the U.S. I’m encouraged by our partnerships and acquisitions progress into Q4 2021 and look forward to the coming months.”
Sit back, relax and watch this powerful interview.
We are pleased to launch our new logo and announce that the Company will unite its subsidiaries and brands under a single Novamind brand.
Novamind is investing in a revitalized and unified brand following a year of significant growth including expansion into new states, launching new clinics and research sites and bringing to market several innovative mental health care offerings.
Novamind’s new logo is now live on its corporate website and social media platforms. The logo integrates and flows across all digital and physical properties, and represents Novamind’s core beliefs in hope, healing and transformation. The open doorway at the centre of the logo, working in conjunction with the radiating lines, is an invitation towards an improved way of life—one where taking care of mental health is a priority.
The logo reveal kicks off the multi-phase rebrand of the Company’s network of clinics and research sites, expected to be complete in 2022. The Company is also improving its website to scale alongside its growth strategy and better serve diverse audiences with enhanced content and tools. Taking inspiration from the revitalized logo, the website will provide an accessible digital entry point to Novamind’s world-class care and clinical research offerings.
Yaron Conforti, CEO and Director, commented: “The new logo, rebrand and website reflects our rapid evolution over the last year. It’s an exciting opportunity to unify our current and future assets under one unique identity that will become a trusted and recognized name for innovative mental healthcare in communities across the U.S.”
In this episode of the Psychedelic Therapy Frontiers podcast, Hannah Cross is back and joinsDr. Steve Thayer and Dr. Reid Robison to explore psycho-spiritual emergencies. Hannah is a licensed clinical social worker, therapist, reiki master and yoga teacher.
Could MDMA-assisted therapy be a treatment for alcohol use disorder? A new study says psychotherapy under the influence of the drug MDMA could help patients process the traumatic experiences that are often the root cause of this condition. Psychedelics have long been considered in the treatment of alcohol use disorder, with scientists in the ‘60s hypothesizing that it might. Click the link above to learn more about MDMA and alcohol use disorder. Learn more about LSD and alcohol use disorder here.
Virtual reality could be the next great digital frontier. And thinking has already begun for how it can advance the mental health revolution we are currently in. “The use of VR in medical settings to provide emotional care is not a new concept. Over the past several years VR has been employed with greater frequency and effectiveness in ways large and small. Recently, the staff at a hospital in Long Beach, California, used virtual reality tech in a simple yet valuable context, distracting young patients during medical procedures like removing a cast.”
Your genetics may hold some clues as to how psychedelics might affect you. But the test isn’t perfect and results should be taken with a grain of salt: “The test covers five different DNA markers for psychedelic sensitivity, metabolism, and mental health risk. However, some of the conclusions drawn by HaluGen are oversimplified or based on outdated science, experts told VICE.”
Researchers from the Yale Department of Psychiatry were awarded a US$2 million grant for a first-of-its-kind clinical trial. “Holmes and Sanacora will compare the efficacy of ketamine (six infusions administered intravenously over three weeks) to placebo in 50 individuals with Parkinson’s disease and depression. Using cutting-edge brain imaging they will also study the mechanistic effects of ketamine on synaptic connections and functional networks in the brain.” In a similar vein, we recently launched the Psychedelic Palliative Care by Novamind program earlier this fall. It’s a program that supports the mental health of adults coping with serious or chronic physical illness such as cancer, heart disease, Parkinson’s or pain conditions. Learn more here.
Posted by AGORACOM-JC
at 4:03 PM on Wednesday, November 24th, 2021
Liquid Avatar is a global blockchain & personal identity solutions company specializing in empowering individuals to manage, control and generate value from their biometrically-verified Self Sovereign digital Identity (“SSI”) .. … while also providing businesses and governments the ability to easily integrate digital wallets and digital identity solutions through its Liquid Avatar platform (www.liquidavatar.com).
As the digital universe has continued to expand, there is an ever-increasing need to verify online identity.
The internet has evolved from dot-com read-only to Web 2.0 read and engage to Web3 … which I can best describe as entering the Matrix for some older viewers amongst us OR RP1 for our younger investors.
The technical term is the Metaverse. First coined in Neal Stephenson’s 1992 sci-fi novel, Snow Crash, as a concept that blends digital and physical existence.
Oasis’ client Aftermath Islands has received significant interest on the sales from its initial Phase 1 launch of Virtual Land and is now launching its initial Virtual Land sales for Phase 2 of its metaverse platform. Like the previous Phase 1 group of islands, some of which are already sold out.
Meta Hero Project
A new 3D Meta Hero Project Avatar platform that allows users to fully customize and personalize their avatar with their life-like body type and photo-realistic face, together with unique skills and powers from a range of classes, giving them the ability to integrate with digital identity and be part of new and emerging online games and metaverse activities, including Aftermath Islands.
Meta Heroes combine gameplay, interactive engagement, and socialization seamlessly through fully controllable, high-quality, personalized 3D avatars. Meta Hero Project will be one of the first photo-realistic, life-like, customizable, personalized, and interactive NFTs, fully rigged for animation and play and that will conform to game, emerging metaverse, and digital identity standards.
This is next-level stuff that you aren’t going to want to miss. Sit back, relax and watch this powerful interview.
Posted by AGORACOM-JC
at 5:10 PM on Tuesday, November 23rd, 2021
FansUnite Entertainment $FANS $FUNFF is a global sports and entertainment company, focusing on technology for online gambling. Specifically, they have produced a one-of-a-kind complete iGaming platform, with a sports and esports focus geared for the next generation of online bettors and casino players. The platform operates multiple B2C brands and B2B software for the online gambling industry. More than just talk FANS has:
300,000+ registered members
$CDN 350,000,000 in betting volume over the last 3 years
Gambling licenses in the highly coveted U.K. and Malta
A successful $25,000,000 raise earlier this year to arm the company for acquisitions.
Today they announced a $USD 58,000,000 acquisition that can best be described by CEO Scott Burton in this powerful quote:
“The acquisition of American Affiliate represents the most significant milestone for FansUnite to date,” said Scott Burton, CEO of FansUnite Entertainment. “This transformative transaction will provide us further access to the lucrative U.S. regulated sports betting and online gambling market while generating accretive, high-margin revenue, expanding our leadership team, and accelerating the growth of our company’s footprint in the global gambling market.”
Some of the highlights of this acquisition are as follows:
Revenue and EBITDA Growth: American Affiliate has produced trailing 12 months unaudited revenue and EBITDA of US$13.1 million and US$6.0 million respectively.
High-Value Customer Base: American Affiliate’s assets have generated over 150,000 new depositing customers for legal U.S. online betting operators.
Partnerships with Tier-One Sportsbooks: Partnerships with leading sportsbooks and casinos including BetMGM, DraftKings, FanDuel, PointsBet, Underdog Fantasy, WynnBet, and more.
Strong Alignment with Existing Management and Shareholders: Consideration shares to be issued at a 42% premium to market price with share restrictions over a three-year period
World-Class Executive Team: Tier-one executive and management team with a history of success and scale in the U.S. gaming market
Leading Intellectual Property Portfolio: Category-leading portfolio of proprietary technology.
Posted by AGORACOM-JC
at 8:48 AM on Thursday, November 18th, 2021
The internet has evolved from Web 1.0 (dot-com read only) back in the 90’s to Web 2.0 (read and write) over the last 15 years to the current emergence of Web3 … which I can best describe as entering the Matrix (for some older investors) OR Ready Player 1 for our younger investors.
The technical term is the Metaverse. It’s already a $30B market BUT we haven’t seen anything yet based on the following:
According to Strategy Analytics, the global metaverse market size is projected to increase ~ 1,000% to $280 billion by 2025 from $30.7 billion in 2021 SOURCE … but we think that’s a very conservative estimate
Bloomberg Intelligence believes the Metaverse can reach $800 billion by 2024.
South Korea’s biggest asset manager, Samsung Asset Management, recently launched a metaverse fund.
IS THE METAVERSE HERE
It was always coming but we just didn’t know when because we needed two things to happen – the evolution of technology and acceptance.
The technology is now here thanks to AR, VR, Blockchain and the rise of NFTs, which Liquid Avatar has been at the forefront of since Day 1.
Acceptance was always a bit more of a wildcard because it is a pretty big shift – but the Covid-19 pandemic was the catalyst that drove the internet to the next stage of its evolution – the ‘Metaverse’ where cyberspace becomes more of an interactive 3D space with commerce and networking alongside content, much like the worlds in popular games such as Fortnite and Roblox,
Roundhill Investments, a major ETF sponsor focused on thematic and sector-specific investing stated “We Believe More Virtual Platforms Will Emerge … New virtual platforms will emerge, and they will likely exceed today’s leaders”
ENTER LIQUID AVATAR METAVERSE ENTRY WITH AFTERMATH ISLANDS
Two weeks ago Liquid Avatar announced that it’s Sale of Virtual Land NFTs in Aftermath Islands Metaverse Went Live . Though we don’t have official numbers yet, we do know that all virtual land in “Musk Manor” and “Bitcoin Bay” sold out pretty fast, so it’s safe to say that Aftermath Islands is off to great success.
With that kind of success, it’s no wonder $LQID is planning to showcase its Metaverse chops at what might be the biggest Comic Con of the year as we come out of COVID – LA Comic Con – where they were named as the Digital Innovation Partner back on October 26. Subsequently $LQID announced announced Hosting a Metaverse Mainstage Panel at Los Angeles Comic Con, Featuring Aftermath Islands ..where it will also has over 1,500 square feet of prime floor space that will showcase NFT subsidiary Oasis Studios, Aftermath Islands, comic and graphics art partner Apex Comics Group … and as yet to be announced “surprises”.
This week $LQID added another great element to Aftermath Islands, the first ever age verified islands as follows:
These are powerful initiatives because the genesis of $LQID is biometrically verified digital identity … giving the Company a substantial advantage in the race towards building the Metaverse.
If you’re a small cap investor that wants exposure to The Metaverse, make sure to watch this great interview with CEO David Lucatch.
In this episode of the podcast, Dr. Steve Thayer and Dr. Reid Robison are joined for the second time by Dr. Paul Thielking, MD. He is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind.
Chief Scientific Officer, Dr. Paul Thielking speaks with Amanda Siebert from The Dales Report on the potential of psychedelics for palliative care and the role of group therapy.
Chief Medical Officer, Dr. Reid Robison discusses Novamind being granted DEA licenses for psilocybin research and our new Psychedelic Palliative Care program with AGORACOM.
Dr. Reid Robison opened the PSYCH Investor Summit with a keynote address presenting Novamind’s positioning and the rise and rollout of psychedelic medicine.
We are pleased to announce we have been granted Schedule 1 licenses (the “DEA Licenses”) from the U.S. Drug Enforcement Agency (DEA) for Dr. Reid Robison, Chief Medical Officer, and Dr. Paul Thielking, Chief Scientific Officer. The DEA Licenses are required for research sites planning to host clinical trials for psilocybin, enabling principal investigators to store and administer this controlled substance.
“Obtaining the DEA Licenses is a critical step towards hosting clinical trials for psilocybin-assisted psychotherapy,” commented Dr. Robison. “We’re proud of our clinical research organization’s track record investigating innovative solutions for central nervous system conditions. This milestone reflects our expertise and enables us to continue on our mission to create breakthroughs in mental health treatment.”
Psilocybin has shown significant positive outcomes for people with major depressive disorder¹ and for reducing anxiety and depression in people with life-threatening cancer.² As of today, there are over 50 clinical studies actively examining the use of psilocybin, as listed on www.clinicaltrials.gov.
“The DEA Licenses are timely,” said Dr. Thielking, who last week launched Psychedelic Palliative Care by Novamind, a first of its kind program to support the mental health of patients and families struggling with serious illness. “We anticipate that this progress will accelerate the approval process for us to become a research site for additional psychedelic clinical studies in the future.”
Time magazine writes how the burnout, trauma and stress caused by the COVID-19 pandemic is opening the door to accelerated psychedelic research. “It’s no coincidence that psychedelics are entering the conversation at the moment we most sorely need new ideas in mental health care. The world is experiencing mass trauma from COVID-19.” It’s especially true with frontline workers. The stats are alarming. The need has never been more apparent. It’s why we launched our Frontline Ketamine-Assisted Psychotherapy treatment program earlier this year. We’re providing healthcare workers with critical mental healthcare. You can learn more about the program here.
Therapeutic Goods Administration (TGA) in Australia is currently evaluating a proposal to reschedule two prominent psychedelics into a less restrictive classification. Mind Medicine Australia submitted the proposal to the government and “has the support of world leading experts in psychedelic research.” Novamind Chief Medical Officer, Dr. Reid Robison, will be presenting at the Mind Medicine Australia summit in November. Get your tickets here.
Could psychedelics follow the same path of cannabis toward legalization and regulation for medical purposes? It’s a question Luis Millán asks for National Magazine. “Despite the legal uncertainty, business is hopeful. Some stock market speculators believe psychedelics will follow in the footsteps of the cannabis industry and become the next billion-dollar business.”
Posted by AGORACOM-JC
at 4:12 PM on Wednesday, October 13th, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
Q3 Highlights:
Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
Record 9 months revenues at $10.2 million , up 94%
2 Group Purchasing Organizations listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products
The 2 multi-year product listings commenced on October 1, 2021
The GPOs together represent more than 700 hospitals and healthcare facilities across 5 provinces including Ontario
The agreement above supports $30M annual revenue target From blood thinner product alone!
As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.
Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss self-compassion, why it is so hard (but so important) to forgive, and how to detox from judgement.
Novamind’s Chief Medical Officer opened the Summit with a keynote drawing on his career as a pioneering psychiatrist and researcher in ketamine-assisted psychotherapy. Check back next week for footage of his presentation.
We are pleased to launch Psychedelic Palliative Care by Novamind (the “Palliative Program”) at its recently opened clinic and research site in Murray, Utah.
Among the first-of-its-kind, the Palliative Program combines psychedelic medicine with psychotherapy, workshops, multi-day immersive retreats and group support for palliative care patients and families who are coping with chronic and serious illness.
“Patients receiving palliative care have higher rates of depression than the general population. Unfortunately, standard anti-depression and anti-anxiety treatments do not work for everyone, can cause side effects, and can take up to eight weeks to work,” explained Dr. Paul Thielking, Chief Scientific Officer (CSO) of Novamind. “Due to psychedelic medicine’s generally low side effect burden and fast-acting nature, it shows promise for patients who are physically ill and might have limited life expectancies.”
Through Novamind’s clinical research division, the Palliative Program will host studies to investigate the use of psychedelic medicine including ketamine and establish the infrastructure for future clinical studies examining psilocybin. This work will build on notable studies from New York University and Johns Hopkins University, which demonstrated psilocybin’s significant immediate and sustained improvements in anxiety and depression symptoms in cancer patients.
Prior to his role as Novamind’s CSO, Dr. Thielking developed ketamine-assisted treatment protocols for cancer patients experiencing depression at the University of Utah Huntsman Cancer Institute (HCI). He also pioneered an ongoing HCI study examining the feasibility of group-administered psilocybin-assisted psychotherapy for cancer patients experiencing depression. Dr. Thielking leads the Palliative Program’s multidisciplinary team of mental health professionals specialized in palliative care and psychedelic-assisted psychotherapy.
“Our healthcare system struggles to support the millions of Americans dealing with emotional, spiritual and psychological suffering associated with chronic or serious illness,” noted Dr. Thielking. “Psychedelic Palliative Care by Novamind is designed to address this need, bringing together fast-acting medicine, innovative treatment options and therapeutic expertise in a safe, nurturing environment.”
We announced our participation in two upcoming virtual investor conferences on Wednesday, October 13, 2021.
Novamind’s CEO and Director, Yaron Conforti, will present our progress towards expanding access to psychedelic medicine in the U.S., including the recent opening of our sixth clinic and the newly launched Psychedelic Palliative Care program.
Virtual LD Micro Main Event XIV Date: October 13, 2021 Time: 10:30 AM to 11:00 AM EST Register and watch live here: me21.mysequire.com
In a collaboration with DoubleBlind magazine, Shelby Hartman and Madison Margolin explore how professional and economic systems are changing as the psychedelic revolution continues to grow. It’s not just about growth, though, but also the way we work. “What psychedelics offer is an invitation to look at professional and economic systems more, well, psychedelically.”
Covering Rick Doblin’s talk at the 2021 Annual Psychiatric Times World CME Conference, Leah Kuntz writes about what other conditions MDMA could treat including “depression, alcohol dependence, obsessive compulsive disorder, and even demoralization in AIDS survivors.” We look forward to further research on MDMA and will work to create treatment protocols for an array of mental health conditions, similar to our work with ketamine.
“According to estimates by the World Health Organization, about 300 million people worldwide live with depression.” It’s a stat that illuminates why there is so much urgency to bring psychedelic-assisted therapies to the world. We want to make a difference, to improve the quality of life for people suffering from depression and other mental health conditions, regardless of the psychedelic being used to bring about that lasting change. From Chief Medical Officer, Dr. Reid Robison: “I’m always touched by stories of hope and healing that come from witnessing the psychedelic modalities in action.”
Posted by AGORACOM-JC
at 4:32 PM on Thursday, October 7th, 2021
FOBI is a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement in the brick and mortar space. From that core technology they have built a technology stack on top of it that is second to none.
They have created multiple successful applications that, for the purposes of this interview, includes their venue management platform that has been deployed at multiple NCAA tournaments, a recent MGM Resorts Championship PGA Event in Las Vega and most recently signed a deal to bring their venue management solutions to the Canadian Hockey League, the world’s largest development hockey league with 9 Million Fan Visits in 2019.
How important is this acquisition? CEO Rob Anson says it best:
“This represents a key achievement for Fobi and its shareholders. This acquisition of PassWallet positions Fobi as an up and coming leader in the digital wallet space. The company has made great strides this year and this key strategic development positions us extremely well, enabling us to leverage and monetize on a standard ARPU model (average revenue per user). With over 6 million downloads currently, management believes that by leveraging our artificial intelligence and data solutions as well as the integration of Fobi’s marketing power together with the global wallet pass growth rates, that this number will grow significantly in 2022. Coupled with further untapped opportunity and an addressable market of over 150 countries that are currently not serviced by Google Pay, management anticipates that with this acquisition Fobi is now well positioned to expand into the FinTech space.”
Sit back and watch this powerful interview with CEO Rob Anson AND… Fobi SVP of Corporate Strategy & Corporate Development Richard Lee.
